Discourage Using the New Oral Antiplatelet Drug Zontivity Alone
September 2014
You'll hear controversy about the new oral antiplatelet drug, Zontivity (zon-TIV-i-tee, vorapaxar).
It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.
It's approved for use with low-dose aspirin and/or clopidogrel after a heart attack or in patients with peripheral artery disease...to further reduce CV events or death.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote